Specify a stock or a cryptocurrency in the search bar to get a summary
IO Biotech Inc
IOBTIO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark. Address: Ole Maaløes Vej 3, Copenhagen, Denmark, 2200
Analytics
WallStreet Target Price
8.2 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures IOBT
Dividend Analytics IOBT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History IOBT
Stock Valuation IOBT
Financials IOBT
Results | 2019 | Dynamics |